- Home
- SRTS vs VTVT Comparison
SRTS vs VTVT Comparison
Compare SRTS & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- VTVT
- Stock Information
- Founded
- SRTS 2010
- VTVT 2015
- Country
- SRTS United States
- VTVT United States
- Employees
- SRTS N/A
- VTVT N/A
- Industry
- SRTS Medical/Dental Instruments
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- VTVT Health Care
- Exchange
- SRTS Nasdaq
- VTVT Nasdaq
- Market Cap
- SRTS 52.9M
- VTVT 54.4M
- IPO Year
- SRTS 2016
- VTVT 2015
- Fundamental
- Price
- SRTS $4.24
- VTVT $25.50
- Analyst Decision
- SRTS Strong Buy
- VTVT Strong Buy
- Analyst Count
- SRTS 3
- VTVT 2
- Target Price
- SRTS $8.00
- VTVT $35.50
- AVG Volume (30 Days)
- SRTS 143.2K
- VTVT 4.6K
- Earning Date
- SRTS 11-06-2025
- VTVT 11-06-2025
- Dividend Yield
- SRTS N/A
- VTVT N/A
- EPS Growth
- SRTS N/A
- VTVT N/A
- EPS
- SRTS N/A
- VTVT N/A
- Revenue
- SRTS $35,609,000.00
- VTVT $17,000.00
- Revenue This Year
- SRTS N/A
- VTVT N/A
- Revenue Next Year
- SRTS $47.33
- VTVT N/A
- P/E Ratio
- SRTS N/A
- VTVT N/A
- Revenue Growth
- SRTS N/A
- VTVT N/A
- 52 Week Low
- SRTS $3.03
- VTVT $12.62
- 52 Week High
- SRTS $9.33
- VTVT $27.00
- Technical
- Relative Strength Index (RSI)
- SRTS 70.02
- VTVT 73.00
- Support Level
- SRTS $3.07
- VTVT $22.45
- Resistance Level
- SRTS $4.19
- VTVT $25.30
- Average True Range (ATR)
- SRTS 0.29
- VTVT 1.40
- MACD
- SRTS 0.08
- VTVT 0.39
- Stochastic Oscillator
- SRTS 100.00
- VTVT 80.56
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.